How is Olumiant impacting the RA treatment landscape?
After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, Eli Lilly/Incyte’s Olumiant (baricitinib) has managed to get first-to-market advantage in Europe. KOL’s weigh in on how Olumiant is faring in the EU, how its availability is impacting Xeljanz, as well as its chances to garner FDA approval. KOLs also examine Sanofi/Regeneron’s Kevzara (sarilumab) and how this new IL-6 inhibitor is faring. Furthermore, the experts discuss how AbbVie’s upadacitinib (ABT 494) and Galapagos/Gilead Sciences’ filgotinib shape up in an ever competitive JAK inhibitor market, as well as how Can-Fite’s piclidenoson (CF 101) could disrupt the treatment paradigm. Experts also give their views on biosimilar anti-TNF uptake and the challenges branded anti-TNFs may face. Twelve US and European KOLs offer their candid insights on these issues and more.
Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
“Upadacitinib is showing signs of JAK2 inhibition as well. Whether this is a good thing or a bad thing, nobody knows.”
European Key Opinion Leader
“Rituximab has always been kind of niche drug, especially in RA, it's more the end of the line. In RA it’s always going to be third or fourth line biologic.”
US Key Opinion Leader
Marketed Therapies
Pipeline Therapies
Earlier stage
KOLs from North America
KOLs from Europe
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved